REVIEW PAPER
Complications after chemotherapy in the practice of a specialist in internal medicine
1
Katedra i Klinika Chorób Wewnętrznych UM w Lublinie
Corresponding author
Andrzej Prystupa
Andrzej Prystupa, Katedra i Klinika Chorób Wewnętrznych UM w Lublinie, ul. Staszica 16
Andrzej Prystupa, Katedra i Klinika Chorób Wewnętrznych UM w Lublinie, ul. Staszica 16
Med Og Nauk Zdr. 2014;20(4):444-448
KEYWORDS
ABSTRACT
Introduction:
In practice, internal medicine in the light of advances in cancer treatment there is the problem of management of patients undergoing cytotoxic therapy, and during their chemotherapy.
Aim:
The aim of the study was to present the problem of development and treatment of major oncological complications associated with the therapy to destroy the cancer cells; at the same time, it also affects healthy organs and systems of the body. Major complications concern the cardiovascular system, haematopoietic system, central and peripheral nervous system and the urinary system
Methodology:
A review of the literature available at on-line databases in 1998–2013 were used to update these problems.
Summary:
Through knowledge of the complications, proper preparation of cancer patients and appropriate care during treatment, the effects of aggressive treatment of chemotherapy can be minimalized.
In practice, internal medicine in the light of advances in cancer treatment there is the problem of management of patients undergoing cytotoxic therapy, and during their chemotherapy.
Aim:
The aim of the study was to present the problem of development and treatment of major oncological complications associated with the therapy to destroy the cancer cells; at the same time, it also affects healthy organs and systems of the body. Major complications concern the cardiovascular system, haematopoietic system, central and peripheral nervous system and the urinary system
Methodology:
A review of the literature available at on-line databases in 1998–2013 were used to update these problems.
Summary:
Through knowledge of the complications, proper preparation of cancer patients and appropriate care during treatment, the effects of aggressive treatment of chemotherapy can be minimalized.
REFERENCES (33)
2.
Minotti G, Ronchi R, Salvatorelli E, i wsp. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res. 2001; 61: 8422–8488.
3.
Tallaj JA, Franco V, Rayburn BK, i wsp. Resoponse of doxorubicin¬-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005; 24: 2196–2201.
4.
Shaik N, Yusuf SW, Stafford J, i wsp. The role valsartan and carvedilol in patients with chemotherapy associated cardiomyopathy who are intolerant to angiotensin converting enzyme inhibitors. J Card Fail. 2005; (supl. 11): 87.
5.
Paulides M, Kremers A, Stohr W, i wsp. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer. 2006; 46: 489–495.
6.
Łącko A, Włodarska I, Zymliński R, Mazur G, Wrobel T, Gisterek I. Kardiotoksyczność leczenia przeciwnowotworowego. Pol Merkuriusz Lek. 2002; 13: 79–85.
7.
Schuchter LM, Hensley ML, Meropol NJ, Winer EP. American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002; 20: 2895–2903.
8.
Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2005; 25: CD003917.
9.
Młot B, Rzepecki P. Kardiotoksyczność leczenia onkologicznego. Nowotwory. Journal of Oncology. 2010; 60(6): 536–547.
10.
Brzeziński K. Polineuropatia wywołana chemioterapią. Część I. Patofizjologia Współczesna Onkol. 2012; 16(1): 79–85.
11.
Casanova-Molla J, Grau-Junyent JM, Morales M, Valls-Solé J. On the relationship between nociceptive evoked potentials and intraepidermal nerve fiber density in painful sensory polyneuropathies. Pain 2011; 152: 410–8.
12.
Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR, et al. Taxolinduced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004; 109: 132–142.
13.
Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel-and vincristi¬neinduced painful peripheral neuropathy. Pain 2004; 109: 150–161.
14.
Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006; 122: 245–257.
15.
Curran MP, Plosker GL. Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer. Drugs Aging 2002; 19: 695–721.
16.
Moudgil SS, Riggs JE. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother 2000; 34: 1136–8.
17.
Huszno J, Nowara E. Farmakokinetyka i farmakogenetyka w systemowym leczeniu chorych na raka piersi. Onkol Prak Klin. 2010; 6(4): 159–170.
18.
Gorczyca M. Biotransformacja leków. W: Zejc A, Gorczyca M, (red.). Chemia leków. Warszawa: PZWL Wydawnictwo Lekarskie; 2008; 1: 756–773.
19.
Orzechowska-Juzwenko K. Leki stosowane w leczeniu nowotworów. Janiec W, (red.). Farmakodynamika. Podręcznik dla studentów farmacji. Warszawa: Wydawnictwo Lekarskie PZWL; 2009; 2: 989–1022.
20.
Mutschler E, Geisslinger G, Kroemer HK, Ruth P, Schafer-Korting M. Chemioterapia nowotworów złośliwych. W: Buczko W, (red.). Kompen¬dium farmakologii i toksykologii Mutschlera. 2007; 413–428.
21.
Pagano L, Caira M, Cuenca-Estrella M. The management of febr ile neutropenia in the posakonazole era: a new challenge? Haematologica 2012; 97(7): 963–965.
22.
Bow EJ. There should be no escape for febr ile neutropenic cancer payients: the dearth of effetive antibacterial drugs threatens anticancer efficacy. J Antimicrob Chemother. 2013; 68(3): 492–495. doi: 10.1093/ jac/dks512.
23.
Cherif H, Axdorph U, Kalin M, et al. Clinical experience of granulocyte transfusion in the management of neutropenic patients with haematological malignancies and severe infection. Scandinavian Journal of Infectious Disease. 2013; 45: 112–116.
24.
Van Dalen EC, Mank A, Leclercq E, et al. Low bacterial diet versus control diet to prevent infection in cancer patients treated with che-motherapy causing episodes of neutropenia (Review). The Cochrane Library 2012; 9: 1–33.
25.
Lindsey RB, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2012; 10: 1412–1445.
26.
Perisano C, Maffuli N, Colelli P, et al. Misdiagnosis of soft tissue sarcomas of the lower limb associated with deep venous thrombosis: report of two cases and review of the literature. BMC Musculoskeletal Disorders. 2012; 14(64): 1–6.
27.
Trujillo-Santos J, Monreal M. Management of unsuspected pulmonary embolism in cancer patients. Expert Rev Hematol. 2013; 6(1): 83–89.
28.
Howard LS, Hughes RJ. NICE guideline: management of venous thromboembolic disease and role of thrombophilia testing. Thorax 2013; 68: 391–393. doi:10.1136/thoraxjnl-2012–202376.
29.
Lee AY, Rickles FR, Julian AJ, et al. Randomised comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005; 23: 2123–2129.
30.
Hettiarachchi RJK, Lok J, Prins MH, et al. Undiagnosed malignancy in patients with deep vein thrombosis. Cancer 1998; 83: 180–185.
31.
Maj S. Polekowe powikłania hematologiczne. Postępy Nauk Medycznych 2000; 4: 17–28.
32.
Mańko J, Jawniak D, Walter-Croneck A, et al. Ocena skuteczności i bezpieczeństwa stosowania biopodobnego granulocytowego czynnika wzrostu (Zarzio) w porównaniu do filgrastimu (Neupogen) w mobili¬zacji hematpoetycznych komórek macierzystych. Acta Haematologica Polonica 2011; 42(3): 501–506.
33.
Hus I, Dmoszyńska A, Cioch M, Zastosowanie erytropetyny w leczeniu niedokrwistości w przebiegu nowotworów układu krwiotwórczego. Acta Haematologica Polonica 2002; 33(1): 55–66.
Share
RELATED ARTICLE
| eISSN: | 2084-4905 |
| ISSN: | 2083-4543 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
